Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Cardiometabolic disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cardiometabolic syndrome (CMS) is a combination of metabolic dysfunctions mainly characterized by insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, and central adiposity. CMS is now recognized as a disease entity by the World Health Organization and the American Society of Endocrinology. 1. .
Mao-b inhibitors useful for treating obesity
InactiveUS20070078172A1Reduce the amount requiredEfficient reductionBiocideAnimal repellantsDyslipidemiaBlood lipids
The invention provides a method of treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.
Owner:JENRIN DISCOVERY
Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
ActiveUS20150038503A1Significant positive effectBiocideSenses disorderPyridazineCardiometabolic disease
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
Owner:GENFIT SA
MAO-B inhibitors useful for treating obesity
The invention provides novel compounds of formulae I and II: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
Owner:JENRIN DISCOVERY
Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases
ActiveUS20180255821A1Improve adaptabilityEffective weightBacteriaMetabolism disorderSymbiotic bacteriaCardiometabolic disease
The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a165 rRNA sequence SEQ ID NO: 2.
Owner:INT NUTRITION RES
Pcsk9 antagonist compounds
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
Owner:MERCK SHARP & DOHME LLC
Pcsk9 antagonist compounds
Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof:where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
Owner:MERCK SHARP & DOHME LLC
Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.
Owner:COLORADO STATE UNIVERSITY
Hri activators useful for the treatment of cardiometabolic diseases
Compounds of formula (I) include: X is CH or N, preferably CH; n is 1-5, preferably 1-2; m is 0-5, preferably 1-2; and, when m is 2-5, two of the R2 radicals taken together with two adjacent carbons of the benzene ring can form a 5- or 6-membered heterocyclic ring fused with the benzene ring. Compounds of formula (I) are heme-regulated inhibitor (HRI) activators and useful for prevention or treatment of cardiometabolic diseases such as metabolic syndrome, obesity, insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease, steatosis, non-alcoholic steatohepatitis, hypertension, dyslipidemia, atherosclerosis, and heart disease.
Owner:UNIV DE BARCELONA
Machine learning prediction of therapy response
ActiveUS11227690B1Symptoms improvedLower blood sugar levelsMedical simulationMedical data miningMedicineCardiometabolic disease
A method comprising: receiving, for each of a plurality of subjects, each having a specified type of cardiovascular or cardiometabolic disease and receiving at least one specified therapy from a set of therapies for treating cardiovascular and cardiometabolic diseases, a first score representing a first genetic predisposition in said subject to respond to one or more of said set of therapies; at a training stage, training a machine learning model on a training set comprising: (i) all of said first scores, and labels associated with a response in each of said subjects to said at least one specified therapy; and at an inference stage, apply said trained machine learning model to a target said first score received with respect to a target subject, to predict a response in said target subject to at least one of said therapies in said set.
Owner:OPENDNA LTD
Modulation of agpat5 expression
ActiveUS20170321216A1Organic active ingredientsMetabolism disorderCardiometabolic diseasePhysiological markers
Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and / or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.
Owner:RGT UNIV OF CALIFORNIA +1
Compositions comprising 15-hepe and/or 15-hetre and methods of treating or preventing cardiometabolic disease, metabolic syndrome, and/or related diseases
InactiveCN112930211AOrganic active ingredientsMetabolism disorderCardiometabolic diseasePharmacology
The present disclosure relates to methods of treating or preventing metabolic syndrome and / or cardiometabolic disease by administration of 15-HEPE, 15-HETrE, or compositions thereof.
Owner:AFIMMUNE LTD
Targeted delivery of therapeutic agents to human adipocytes
ActiveUS20210145745A1Minimise systemic exposureHigh indexSpecial deliveryHydroxy compound active ingredientsCardiometabolic diseaseLipid Body
Compositions and methods relating to modulating thermogenic regulation are disclosed. The compositions and methods can be used to treat diseases or conditions such as obesity or cardiometabolic disorders such as type 2 diabetes mellitus, NAFLD and NASH. Compositions include an adipocyte-targeting composition that includes a therapeutic agent capable of modulating thermogenic regulation, a targeting element facilitating cellular uptake and delivery of the therapeutic agent to a targeted adipocyte, and liposomal particles comprising sphingomyelin, DMPC, and cholesterol, wherein the liposomal particles enhance intra-cellular penetration of the therapeutic agent and protect the therapeutic agent from degradation.
Owner:APTAMIR THERAPEUTICS
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.
Owner:MERCK SHARP & DOHME LLC +1
Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases
ActiveUS10681932B2Effective weightImprove adaptabilityBacteriaMetabolism disorderCardiometabolic diseaseBowels diseases
The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.
Owner:LNC THERAPEUTICS
Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.
Owner:COLORADO STATE UNIVERSITY
Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
ActiveUS20170296548A1Significant positive effectOrganic active ingredientsSenses disorderPyridazineCardiometabolic disease
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
Owner:GENFIT SA
Compositions and methods for treating cardiometabolic diseases and disorders
Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and related medical uses are also described.
Owner:UNIVERSITY OF PRINCE EDWARD ISLAND
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
InactiveUS20200330459A1Reducing cardiac fibrosisImprove heart functionOrganic active ingredientsMetabolism disorderCardiometabolic diseasePharmaceutical drug
The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. The inventors identified osteopontin (OPN) as a critical mediator of adipose tissue remodeling and senescence in obesity and extends this observation to related co-morbidities such as cardiomyopathy. Said result raises the possibility that inhibition of OPN activity may be of value in the prevention of cardiometabolic disease, in particular metabolic cardiomyopathy for which no specific treatment is yet available. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Compositions and methods for treating cardiometabolic diseases and disorders
Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and re lated medical uses are also described.
Owner:UNIVERSITY OF PRINCE EDWARD ISLAND
Method for measuring ldl aggregation
ActiveUS20200025779A1Higher body fat percentageLow saturated fatOrganic active ingredientsMicrobiological testing/measurementAtherosclerotic cardiovascular diseaseA lipoprotein
The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.
Owner:JENNY & ANTTI WIHURI FOUND
Method for measuring LDL aggregation
ActiveUS11442072B2Higher body fat percentageLow saturated fatOrganic active ingredientsMicrobiological testing/measurementAtherosclerotic cardiovascular diseaseA lipoprotein
The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.
Owner:JENNY & ANTTI WIHURI FOUND
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
PendingUS20220088015A1Reducing cardiac fibrosisImprove heart functionOrganic active ingredientsMetabolism disorderCardiometabolic diseasePharmaceutical drug
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
ActiveUS9586963B2Significant positive effectOrganic active ingredientsSenses disorderPyridazineCardiometabolic disease
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
Owner:GENFIT SA
Modulation of AGPAT5 expression
ActiveUS10364433B2Reducing liver triglyceride levelReduce rateOrganic active ingredientsMetabolism disorderLipid formationCardiometabolic disease
Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and / or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.
Owner:RGT UNIV OF CALIFORNIA +1
Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
PendingUS20220023265A1Enhanced signalReducing lipotoxicityMetabolism disorderHeterocyclic compound active ingredientsDecreased body weightCardiometabolic disease
The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and / or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term “cardiometabolic disease” (CMD) to encompass the many facets of this complex syndrome. The inventors assessed the role of the soluble epoxide hydrolase (she) phosphatase domain in metabolism and cardiovascular system, by generating sEH phosphatase knock-in (KI) animals (rats). They unexpectedly revealed that inhibition of the phosphatase domain of sEH improves cardiac systolic function, decreases body weight and increases insulin sensitivity. Moreover under high fat diet, the animals have a decreased body weight gain, were protected against the development of insulin resistance, hepatic steatosis and cardiac hypertrophy. Inhibition of the phosphatase domain of sEH thus represents a new pharmacological target in the treatment of cardiometabolic diseases.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
InactiveUS20150181845A1Organic active ingredientsCompound screeningCardiometabolic diseaseCardio metabolic
Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.
Owner:COLORADO STATE UNIV RES FOUND
PCSK9 antagonists bicyclo-compounds
ActiveUS11306125B2Peptide/protein ingredientsMetabolism disorderCardiometabolic diseaseCoronary heart disease
Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions
Owner:MERCK SHARP & DOHME LLC
Pcsk9 antagonists bicyclo-compounds
ActiveUS20210214395A1Peptide/protein ingredientsMetabolism disorderCardiometabolic diseaseCoronary heart disease
Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions
Owner:MERCK SHARP & DOHME LLC
Machine learning prediction of therapy response
InactiveUS20220102006A1Lower systolic blood pressureLower diastolic blood pressureMedical simulationMedical data miningCardiometabolic diseaseMedicine
Owner:OPENDNA LTD
COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
InactiveUS20200360331A1Increase contentImprove inflammationOrganic active ingredientsMetabolism disorderCardiometabolic diseaseRat heart
The present disclosure relates to methods of treating or preventing metabolic syndrome and / or cardiometabolic disease by administration of 15-HEPE, 15-HETrE, or compositions thereof.
Owner:AFIMMUNE LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com